Report
Teaser, summary, work performed and final results
Periodic Reporting for period 1 - Notid (Novel Target for Treatment of Chronic Inflammatory Diseases)
Teaser
Lipum AB aim to bring to the market a new biological drug (antibody) for treatment of chronic inflammatory diseases. An effective and safe therapeutic alternative has been long expected by the millions of patients that struggle with chronic and debilitating conditions like...
Summary
Lipum AB aim to bring to the market a new biological drug (antibody) for treatment of chronic inflammatory diseases. An effective and safe therapeutic alternative has been long expected by the millions of patients that struggle with chronic and debilitating conditions like Rheumatoid Arthritis (RA) and Inflammatory Bowel Disease (IBD). Lipum focus on the orphan disease Juvenile Idiophatic Arthritis (JIA) that affects children. Apart from the patients’ well-being and quality of life, chronic inflammatory diseases also incur high societal costs of healthcare and lost productivity.
Our approach is based on the 20+ years of research carried out by the founders of Lipum. We have collected scientific evidence that the protein Bile Salt-Stimulated Lipase (BSSL) plays an important role in inflammation. This discovery is used to develop a new therapeutic antibody that will provide a novel mechanism of action with less adverse effects compared to currently used treatments.
Work performed
Lipum has focused on the evaluation of pre-nominated antibody candidates with respect to suitability as final drug candidate. That work has ranged from the chemical and biological evaluation of the antibodies, as well as to initiate and to proceed in establishing a production procedure. Once a sufficient documentation was established the candidate drug SOL-116 was selected and a patent application submitted. In parallel we managed to secure an additional financing of 2.4 M€ via a private placement and to establish an ongoing dialog with venture capital for future funding. To enable this progress the company’s organization was strengthened by recruiting more staff, contracting consultants and service providers to execute development and communication plans.
Final results
We will have a production method for a unique new candidate drug for treatment of chronic inflammatory diseases that has been subject to toxicological testing. The company will then be ready to initiate the clinical program for testing in man.
Website & more info
More info: http://www.lipumpharma.com.